Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

Completed · Phase 3 · Has a placebo group

Conditions studied: Parkinson's Disease, Dyskinesia

In brief

The purpose of this study is to determine if Sarizotan HC1 1 mg b.i.d. (taken twice a day) is effective in the treatment of dyskinesia associated with dopaminergic treatment of Parkinson's disease (PD).

Key facts

Study ID

NCT00105508

Run by

EMD Serono

People needed

506

Starts

2004-09-30

Expected to finish

2006-02-28

Last updated by the study team

2018-07-26

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject is an out-patient.
• The subject presents with a diagnosis of idiopathic Parkinson's disease.
• Prior therapy with all registered Parkinsonian medication is allowed.

You may not qualify if…

• (For female subjects) The subject is pregnant or lactating.
• The subject is participating in another clinical study or has done so within the past 30 days.
• The subject has received neurosurgical intervention related to PD.
• The subject has relevant renal impairment.
• The subject has relevant hepatic impairment.
• The subject is suffering from any dementia or psychiatric illness.
• The subject has a history of allergic asthma.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Huntsville, Alabama, United States
• Study site — La Jolla, California, United States
• Study site — Oxnard, California, United States
• Study site — Sacramento, California, United States
• Study site — Englewood, Colorado, United States
• Study site — Danbury, Connecticut, United States
• Study site — Farmington, Connecticut, United States
• Study site — Jacksonville, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — Maitland, Florida, United States
• Study site — St. Petersburg, Florida, United States
• Study site — Decatur, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Springfield, Illinois, United States
• Study site — Des Moines, Iowa, United States
• Study site — New Orleans, Louisiana, United States
• Study site — Scarborough, Maine, United States
• Study site — Boston, Massachusetts, United States
• Study site — Southfield, Michigan, United States
• Study site — Edison, New Jersey, United States
• Study site — New Hyde Park, New York, United States
• Study site — New Hyde Park, New York, United States
• Study site — New York, New York, United States
• Study site — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.